GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential $1 billion-a-year seller a step closer to market.

AstraZeneca said it would take an $80 million writedown on stocks of its intranasal flu vaccine Flumist Quadrivalent after U.S. health authorities decided they would not use the product.